Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million.
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun
Mark Velleca, CEO of G1 Therapeutics, took the biotechnology company public on Wednesday, raising $105 million. Courtesy of G1 Therapeutics Special to The Herald-Sun

Business

May 17, 2017 11:45 AM

Research Triangle Park company debuts on Nasdaq

Suggested for you

  Comments  

Videos

Editor's Choice Videos